Sélectionner la langue
LILRB2
LILRB2 Informations sur la molécule
| Nom anglais | Leukocyte immunoglobulin-like receptor subfamily B member 2 | Nombre de médicaments commercialisés | 0 |
| Nombre de médicaments cliniques | 11 | Alias de la cible | Leukocyte immunoglobulin-like receptor 2，CD85 antigen-like family member D，Immunoglobulin-like transcript 4，ILT-4，Monocyte/macrophage immunoglobulin-like receptor 10，MIR-10，CD_antigen: CD85d，LILRB2，Leukocyte Immunoglobulin Like Receptor B2，Leucocyte Ig-Like Receptor B2，MIR10，Leukocyte Immunoglobulin-Like Receptor， Subfamily B (With TM And ITIM Domains)， Member 2，Ig-Like Transcript 4，Myeloid Inhibitory Receptor 10，CD85d Antigen，ILT4，LIR2，CD85d，LIR-2，LIRB2 |
| Phase de R&D la plus avancée | Phase 2 Clinical | ||
| Nom anglais | Leukocyte immunoglobulin-like receptor subfamily B member 2 |
| Alias de la cible | Leukocyte immunoglobulin-like receptor 2，CD85 antigen-like family member D，Immunoglobulin-like transcript 4，ILT-4，Monocyte/macrophage immunoglobulin-like receptor 10，MIR-10，CD_antigen: CD85d，LILRB2，Leukocyte Immunoglobulin Like Receptor B2，Leucocyte Ig-Like Receptor B2，MIR10，Leukocyte Immunoglobulin-Like Receptor， Subfamily B (With TM And ITIM Domains)， Member 2，Ig-Like Transcript 4，Myeloid Inhibitory Receptor 10，CD85d Antigen，ILT4，LIR2，CD85d，LIR-2，LIRB2 |
| Nombre de médicaments commercialisés | 0 |
| Nombre de médicaments cliniques | 11 |
| Phase de R&D la plus avancée | Phase 2 Clinical |
LILRB2 Liste de produits
- Attribut
Protein (6)
- Bibliothèque de produits
En ligne (6)
- Espèces
Human (4)Cynomolgus (2)
- Étiquette
His Tag (2)Fc Tag & Avi Tag (1)His Tag & Avi Tag (2)Fc Tag (1)
- Marqueur
Unconjugated (3)Biotin-labeled (3)
| Numéro de produit | Espèces | Système d'expression | Description du produit | Structure protéique | Pureté | Caractéristiques | Pré-commande/Commande |
|---|---|---|---|---|---|---|---|
HOT LI2-H5220 |  Human | HEK293 | Human LILRB2 / CD85d / ILT4 Protein, His Tag, low endotoxin (MALS verified) |  |  |  |  Ajouter au panier |
HOT LI2-H5253 | Human | HEK293 | Human LILRB2 / CD85d / ILT4 Protein, Fc Tag (MALS verified) |  | | | Ajouter au panier |
HOT LI2-H82E7 | Human | HEK293 | Biotinylated Human LILRB2 / CD85d / ILT4 Protein, His,Avitag™ (MALS verified) |  | | | Ajouter au panier |
HOT LI2-H82F5 | Human | HEK293 | Biotinylated Human LILRB2 / CD85d / ILT4 Protein, Fc,Avitag™ (MALS verified) |  | | | Ajouter au panier |
LI2-C52H3 |  Cynomolgus | HEK293 | Cynomolgus LILRB2 / CD85d / ILT4 Protein, His Tag |  | | Ajouter au panier | |
LI2-C82E3 | Cynomolgus | HEK293 | Biotinylated Cynomolgus LILRB2 / CD85d / ILT4 Protein, His,Avitag™ |  | | Ajouter au panier |
Quantité totale6
- 1
LILRB2Contexte de la molécule
Leukocyte immunoglobulin-like receptor subfamily B member 2 (LILRB2) is also known as CD85 antigen-like family member D (CD85d), Immunoglobulin-like transcript 4 (ILT-4), Monocyte / macrophage immunoglobulin-like receptor 10 (MIR-10), which is a member of the the subfamily B class of LIR receptors. LILRB2 is receptor for class I MHC antigens. LILRB2 recognizes a broad spectrum of HLA-A, HLA-B, HLA-C and HLA-G alleles. LILRB2 competes with CD8A for binding to class I MHC antigens. LILRB2 / CD85d inhibits FCGR1A-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions.
LILRB2Alias de la molécule
LILRB2,ILT4,LIR2,MIR10,CD85d
Plateforme de commerce de projets d'anticorps
| Nom du projet | Phase du projet | Type de molécule | Source de molécule | Domain thérapeutique | Indication |
|---|---|---|---|---|---|
| LILRB2 mAb - 01 | PCC | Monoclonal | Humanized Mouse | Solid Tumor | Solid tumor |
Informations sur les médicaments cliniques
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Indication | Essai clinique |
|---|---|---|---|---|---|
| Polzastobart | JTX-8064 | Phase 2 Clinical | Jounce Therapeutics Inc | Neoplasms | Details |
| IO-108 | IO-108 | Phase 2 Clinical | Yiming Biomedical Technology (Hangzhou) Co Ltd | Liver Neoplasms; Solid tumours | Details |
| MK-4830 | MK-4830 | Phase 2 Clinical | Agenus Inc | Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Cystadenocarcinoma, Serous; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Ovarian Neoplasms; Solid tumours | Details |
| SPX-303 | SPX-303 | Phase 2 Clinical | SparX Biopharmaceutical Corp | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Gastroesophageal Junction Neoplasms; Melanoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms | Details |
| OR-502 | OR502; OR-502 | Phase 2 Clinical | OncoResponse Inc | Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Neoplasms; Skin Melanoma; Solid tumours | Details |
| NGM-707 | NGM-707 | Phase 2 Clinical | Merck & Co, NGM Biopharmaceuticals Inc | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Neoplasms; Glioblastoma; Melanoma; Mesothelioma; Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Uterine Cervical Neoplasms | Details |
| AK-150 (Akeso) | AK150; AK-150 | Phase 1 Clinical | Solid tumours | Details | |
| CHS-1000 | CHS-1000 | Phase 1 Clinical | Coherus Biosciences Inc | Solid tumours | Details |
| BMS-986406 | BMS-986406; ONO-7226 | Phase 1 Clinical | Bristol-Myers Squibb Company | Neoplasms | Details |
| CDX-585 | CDX-585; BSI-585 | Phase 1 Clinical | Biosion Inc, Celldex Therapeutics | Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Neoplasms; Fallopian Tube Neoplasms; Head and Neck Neoplasms; Liver Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Peritoneal Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| ES-009 | ES-009 | Phase 1 Clinical | Elpiscience (Shanghai) Biopharma Ltd | Neoplasms; Solid tumours | Details |
- Informations sur la molécule
- Liste de produits
- Informations sur les médicaments cliniques
Partager vers :